| Abstract: | With the launch of sacubitril/valsartan (ARNI), there are new options for the treatment of heart failure (HF). However, ARNI is currently only used in HF patients with reduced ejection fraction (HFrEF). No evidence shows that no modern treatment can reduce mortality in HF patients with preserved ejection fraction (HFpEF). Therefore, it is urgently necessary clarify whether ARNI can be used in the treatment of HFpEF. In the present study, we summarized the research progress of ARNI in the treatment of HFpEF. |
